Observational studyToxins2018
Lumbar Sympathetic Block with Botulinum Toxin Type A and Type B for the Complex Regional Pain Syndrome.
Observational study in Toxins, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Botulinum Toxin A and B Improve Perfusion, Increase Flap Survival, Cause Vasodilation, and Prevent Thrombosis: A Systematic Review and Meta-analysis of Controlled Animal Studies.Hand (New York, N.Y.) · 2023Pooled it
- Management of Neuropathic Pain in Complex Regional Pain Syndrome: A Comprehensive Review.Pain practice : the official journal of World Institute of Pain · 2026Review
- Thoracic sympathetic block with botulinum toxin A for complex regional pain syndrome: a retrospective case series.Interventional pain medicine · 2026Article
- Review
- Perineural Administration of Botulinum Toxin for Chronic Pain Management: A Narrative Review.Pain research & management · 2026Review
- Sensory and Sympathetic Nerve Localization in Mouse Temporomandibular Joint and Knee Joint Neuro-Musculoskeletal Tissues.Orthodontics & craniofacial research · 2025Article
- A brief review of complex regional pain syndrome and current management.Annals of medicine · 2024Review
- Article
- From Toxin to Treatment: A Narrative Review on the Use of Botulinum Toxin for Autonomic Dysfunction.Toxins · 2024Review
- Cracking the Code: The Role of Peripheral Nervous System Signaling in Fracture Repair.Current osteoporosis reports · 2024Review
- Successful therapy of complex regional pain syndrome after hip arthroscopy for femoroacetabular impingement syndrome: a case report.Journal of medical case reports · 2024Article
- The CT-Imaging Location of Lumbar 3 Sympathetic Radiofrequency Thermocoagulation for Sympathetic-Related Diseases Therapy.Journal of pain research · 2024Article
- The complex regional pain syndrome: Diagnosis and management strategies.Neurosciences (Riyadh, Saudi Arabia) · 2023Review
- Pain Modulation in Chronic Musculoskeletal Disorders: Botulinum Toxin, a Descriptive Analysis.Biomedicines · 2023Review
- Meta-Analysis of Effectiveness and Safety of Botulinum Toxin in the Treatment of Complex Regional Pain Syndrome.Life (Basel, Switzerland) · 2022Article
- Subcutaneous BoNT/A Injection for Intractable Pain and Disability in Complex Regional Pain Syndrome: A Case Report.Toxins · 2022Article
- Autonomic Regulation of Nociceptive and Immunologic Changes in a Mouse Model of Complex Regional Pain Syndrome.The journal of pain · 2022Article
- Prolonging Sympathetic Blockade for Complex Regional Pain Syndrome: Is Botulinum Toxin the Answer?Anesthesiology · 2022Article
- Review
- Chemogenetics: Beyond Lesions and Electrodes.Neurosurgery · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A lumbar sympathetic ganglion block (LSB) is a therapeutic method for complex regional pain syndrome (CRPS) affecting the lower limbs. Recently, LSB with botulinum toxin type A and B was introduced as a novel method to achieve longer duration of analgesia. In this study, we compared the botulinum toxin type A (BTA) with botulinum toxin type B (BTB) in performing LSB on patients with CRPS. LSB was performed with either BTA or BTB on patients with CRPS in their lower extremities. The length of time taken for patients to return to the pre-LSB pain score and the adverse effect of LSB with BTA/BTB were investigated. The median length of time taken for the patients to return to the pre-LSB pain score was 15 days for the BTA group and 69 days for the BTB group (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.